cervical squamous intraepithelial lesion
Conditions
Interventions
experimental group :Vaginal combined estrogen cream
control group:no
Sponsors
Jiande Maternal and Child Health Care Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Postmenopausal HSIL patients who were treated from April 2019 to December 2020 were randomly divided into the treatment group and the control group. They were reviewed and approved by the ethics committee of our hospital, and the patients were signed with informed consent. (a) HSIL confirmed by histology of cervical biopsy. (b) Results of TCT testing and high-risk HPV measurements within 3 months. (c) HPV nine-valent vaccine, tetravalent vaccine or bivalent vaccine was not received prior to diagnosis of HSIL. (d) Spontaneous amenorrhea with at least 12 months prior to LEEP surgery. (e) Premenopausal contraception is based on tools and no history of contraceptive use. There is no hormone replacement or vaginal estrogen after menopause. (f) Satisfying follow-up for at least 2 years after operation.
Exclusion criteria
Exclusion criteria: (a) Previously there was a cervical conization and a biopsy confirmed HSIL. (b) Vulvovaginal biopsy combined with VIN. (c) abnormal uterine bleeding after menopause or B-ultrasound intima thickness >5mm.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Surgical specimen size;thin-cytologic test TCT;human papilloma virus, HPV;Vaginal tip morphology;Cervical external morphology; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vaginal cleanliness;Vaginal mucosal atrophy;Postoperative bleeding time; | — |
Countries
China
Contacts
Public ContactKeng Yan
Jiande Maternal and Child Health Care Hospital
Outcome results
None listed